RecruitingPhase 2NCT04183101
Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy
Studying C3 glomerulonephritis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Region Skane
- Principal Investigator
- Diana KarpmanRegion Skåne
- Intervention
- Aliskiren(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 6 years · All sexes
- Timeline
- 2020 – 2029
Study locations (4)
- Sahlgrenska Hospital, Gothenburg, Sweden
- Region Skåne Skåne Universitetssjukhus, Lund, Sweden
- Karolinska Hospital, Stockholm, Sweden
- Akademiska sjukhuset, Uppsala, Sweden
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04183101 on ClinicalTrials.govOther trials for C3 glomerulonephritis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06209736Safety and Efficacy Study of OMS906 in Patients With C3G and ICGNOmeros Corporation
- ACTIVE NOT RECRUITINGPHASE3NCT05809531An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative GlomerulonephritisApellis Pharmaceuticals, Inc.
- RECRUITINGPHASE3NCT03955445Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGNNovartis Pharmaceuticals